CAMP4 Therapeutics Corporation Gain (Loss) on Derivative Instruments, Net, Pretax
CAMP4 Therapeutics Corporation (CAMP) reported Gain (Loss) on Derivative Instruments, Net, Pretax of -$20.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-08-13
- CAMP4 Therapeutics Corporation gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-06-30 was -$20.93M.
- CAMP4 Therapeutics Corporation gain (loss) on derivative instruments, net, pretax for the quarter ending 2026-03-31 was -$6.19M.
- CAMP4 Therapeutics Corporation gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-12-31 was -$28.03M.
- CAMP4 Therapeutics Corporation gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-09-30 was -$1.80M.
- CAMP4 Therapeutics Corporation gain (loss) on derivative instruments, net, pretax for fiscal 2025 was -$29.83M.
- CAMP4 Therapeutics Corporation gain (loss) on derivative instruments, net, pretax for fiscal 2024 was $0.00.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.93M 10-Q · filed 2026-08-13 | -$27.12M 10-Q · filed 2026-08-13 | -$55.15M derived: sum of 3 quarters · filed 2026-08-13 | -$56.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$6.19M 10-Q · filed 2026-05-07 | -$34.22M derived: sum of 2 quarters · filed 2026-05-07 | -$36.02M derived: sum of 3 quarters · filed 2026-05-07 | -$36.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$28.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$29.83M derived: sum of 2 quarters · filed 2026-03-05 | -$29.83M derived: sum of 3 quarters · filed 2026-08-13 | -$29.83M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.80M 10-Q · filed 2025-11-06 | -$1.80M derived: sum of 2 quarters · filed 2026-08-13 | -$1.80M 10-Q · filed 2025-11-06 | -$1.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |